logo
  

China Green Agriculture Q4 Profit Falls, But Sales Up - Quick Facts

China Green Agriculture, Inc. (CGA) Friday reported fourth-quarter net income of $4.3 million or $0.11 per share, significantly down from $14.3 million or $0.51 per share in the prior year.

Net sales for the quarter grew 3.4 percent to $72.2 million from $69.8 million a year ago.

Looking ahead, for the first quarter, the company expects earnings per share to be in the range of $0.18 to $0.24, on revenue of $50.7 million to $54.3 million.

For fiscal year 2015, the company anticipates earnings per share to be in the range of $0.8 to $1.08, on revenues of $254.7 million to $268.8 million.

"As we concluded our recent fiscal year, we look forward to a year with no distractions and expenses from the recently resolved class action lawsuit...Furthermore, as we enter into the new fiscal year, China Green Agriculture is on its way to achieving the early benchmarks of our ten-year plan that was announced in the year of 2011," the company said.

CGA closed Thursday's regular trading at $2.29 on the NYSE. In the pre-market on Friday, the shares are up 11.36 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT